Emerging data suggest Retatru tide , a dual stimulator targeting both GLP-1 and GIP , may represent a promising step forward for obesity management . Preliminary human tests have demonstrated https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide